Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RETREAT(F) treatment withdrawal feasibility study in psoriatic arthritis
2012-003736-23Phase 4Completed
- Sponsor
- University of Leeds
- Start
- Dec 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methotrexate, 5-aminosalicylic acid + sulphasalazine, leflunomide, cyclosporine, etanercept and 3 more in psoriatic arthritis (PsA) (2 arms), sponsored by University of Leeds. Primary endpoints: Number successfully withdrawn from treatment and Minimal disease activity score. Started Dec 2012; status: completed.
02
Drugs
methotrexate5-aminosalicylic acid + sulphasalazineleflunomidecyclosporineetanercept
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2012-003736-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003736-23.